S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Could trawler cams help save world's dwindling fish stocks?
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Could trawler cams help save world's dwindling fish stocks?
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Could trawler cams help save world's dwindling fish stocks?
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Could trawler cams help save world's dwindling fish stocks?
Positive News Sentiment  
NASDAQ:GTHX

G1 Therapeutics - GTHX Stock Forecast, Price & News

$6.38
+0.04 (+0.63%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.16
▼
$6.52
50-Day Range
$5.64
▼
$13.50
52-Week Range
$3.84
▼
$17.49
Volume
989,441 shs
Average Volume
1.02 million shs
Market Capitalization
$273.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.33

G1 Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
375.4% Upside
$30.33 Price Target
Short Interest
Healthy
14.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
1.61mentions of G1 Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$728,280 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.49) to ($2.92) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

228th out of 1,027 stocks

Pharmaceutical Preparations Industry

96th out of 503 stocks

See Top Rated MarketRank™ Stocks Here
GTHX stock logo

About G1 Therapeutics (NASDAQ:GTHX) Stock

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHX Stock News Headlines

December 7, 2022 | finance.yahoo.com
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
November 30, 2022 | americanbankingnews.com
Brokers Set Expectations for G1 Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:GTHX)
November 28, 2022 | bizjournals.com
G1 Therapeutics raises $50M to support commercial, clinical plans
November 28, 2022 | finance.yahoo.com
G1 Therapeutics raises $50M to help lift sales for cancer drug
November 23, 2022 | finance.yahoo.com
G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference
November 22, 2022 | finance.yahoo.com
G1 Therapeutics Announces Closing of Offering of Common Stock
November 18, 2022 | marketwatch.com
G1 Therapeutics Shares Slide Premarket on Public Offering >GTHX
November 18, 2022 | finance.yahoo.com
G1 Therapeutics Announces Proposed Public Offering of Common Stock
November 18, 2022 | finance.yahoo.com
G1 Therapeutics Announces Pricing of Offering of Common Stock
November 3, 2022 | finance.yahoo.com
Newsflash: G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Revenue Forecasts
November 2, 2022 | technews.tmcnet.com
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)
November 2, 2022 | seekingalpha.com
G1 Therapeutics rises as trilaciclib potentially reduces adverse events linked with Trodelvy
November 2, 2022 | finance.yahoo.com
G1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer Drug
October 28, 2022 | finance.yahoo.com
Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?
October 21, 2022 | finance.yahoo.com
G1 Therapeutics (NASDAQ:GTHX investor three-year losses grow to 52% as the stock sheds US$50m this past week
October 19, 2022 | finance.yahoo.com
G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022
October 12, 2022 | finance.yahoo.com
Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?
October 10, 2022 | finance.yahoo.com
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
September 14, 2022 | nasdaq.com
Is G1 Therapeutics (NASDAQ:GTHX) Using Debt Sensibly?
September 7, 2022 | finance.yahoo.com
G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022 | finance.yahoo.com
G1 Therapeutics to Host Virtual R&D Day on September 15, 2022
August 26, 2022 | finance.yahoo.com
G1 Therapeutics (GTHX)'s Technical Outlook is Bright After Key Golden Cross
August 8, 2022 | finance.yahoo.com
Can G1 Therapeutics (GTHX) Climb 150% to Reach the Level Wall Street Analysts Expect?
August 4, 2022 | finance.yahoo.com
G1 Therapeutics, Inc. (GTHX) Q2 2022 Earnings Call Transcript
August 3, 2022 | finance.yahoo.com
G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights
See More Headlines
Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHX Company Calendar

Last Earnings
11/02/2022
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GTHX
CUSIP
N/A
CIK
1560241
Web
www.g1therapeutics.com
Phone
(919) 213-9835
Fax
919-741-5830
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.33
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+375.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.60)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-148,350,000.00
Net Margins
-328.58%
Pretax Margin
-325.45%
Return on Equity
-172.97%
Return on Assets
-74.56%

Debt

Debt-to-Equity Ratio
1.67
Current Ratio
4.24
Quick Ratio
3.86

Sales & Book Value

Annual Sales
$31.48 million
Price / Sales
8.70
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.38 per share
Price / Book
1.89

Miscellaneous

Outstanding Shares
42,912,000
Free Float
39,440,000
Market Cap
$273.78 million
Optionable
Optionable
Beta
1.65

Key Executives

  • Mr. John E. Bailey Jr. (Age 57)
    CEO, Pres & Director
    Comp: $1.04M
  • Ms. Jennifer K. Moses CPA (Age 47)
    Chief Financial Officer
    Comp: $606.27k
  • Dr. Mark A. Velleca M.D.Dr. Mark A. Velleca M.D. (Age 58)
    Ph.D., Sr. Advisor & Director
    Comp: $242.69k
  • Dr. Rajesh K. Malik Ch.B. (Age 63)
    M.B., M.D., Chief Medical Officer and Sr. VP of R&D
    Comp: $596.37k
  • Mr. Mark Avagliano (Age 46)
    Chief Bus. Officer
    Comp: $606.05k
  • Mr. Andrew Perry (Age 49)
    Chief Commercial Officer
    Comp: $568.6k
  • Mr. Terry L. Murdock (Age 62)
    Chief Operating Officer
  • Mr. Alexander D. Smith M.S.
    VP of Technical Operations
  • Dr. Jay C. Strum Ph.D. (Age 58)
    Chief Scientific Officer
  • Mr. William C. Roberts (Age 53)
    VP of Investor Relations & Corp. Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













GTHX Stock - Frequently Asked Questions

Should I buy or sell G1 Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GTHX shares.
View GTHX analyst ratings or view top-rated stocks.

What is G1 Therapeutics' stock price forecast for 2023?

3 brokers have issued 12-month target prices for G1 Therapeutics' shares. Their GTHX share price forecasts range from $25.00 to $34.00. On average, they expect the company's share price to reach $30.33 in the next year. This suggests a possible upside of 378.4% from the stock's current price.
View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts.

How have GTHX shares performed in 2022?

G1 Therapeutics' stock was trading at $10.21 at the beginning of the year. Since then, GTHX stock has decreased by 37.9% and is now trading at $6.34.
View the best growth stocks for 2022 here.

Are investors shorting G1 Therapeutics?

G1 Therapeutics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 6,160,000 shares, a drop of 18.2% from the October 31st total of 7,530,000 shares. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is currently 6.0 days. Currently, 14.9% of the company's shares are short sold.
View G1 Therapeutics' Short Interest.

When is G1 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our GTHX earnings forecast.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) released its earnings results on Wednesday, November, 2nd. The company reported ($0.59) earnings per share for the quarter, topping analysts' consensus estimates of ($0.64) by $0.05. The business earned $23.58 million during the quarter, compared to analysts' expectations of $22.64 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 172.97% and a negative net margin of 328.58%.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (6.84%), Vanguard Group Inc. (3.93%), State Street Corp (3.77%), BlackRock Inc. (3.54%), Marshall Wace LLP (1.47%) and Raymond James & Associates (1.12%). Insiders that own company stock include Glenn P Muir, James S Hanson, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock.
View institutional ownership trends.

How do I buy shares of G1 Therapeutics?

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $6.34.

How much money does G1 Therapeutics make?

G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $272.05 million and generates $31.48 million in revenue each year. The company earns $-148,350,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis.

How many employees does G1 Therapeutics have?

The company employs 148 workers across the globe.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830.

This page (NASDAQ:GTHX) was last updated on 12/8/2022 by MarketBeat.com Staff